NovoCure Limited (NVCR)

Market Cap	2.07B
Revenue (ttm)	605.22M
Net Income (ttm)	-168.63M
Shares Out	109.92M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,412
Open	18.93
Previous Close	18.97
Day's Range	18.41 - 18.93
52-Week Range	11.70 - 34.13
Beta	0.63
Analysts	Strong Buy
Price Target	37.50 (+98.83%)
Earnings Date	May 1, 2025

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,488
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for NVCR stock is "Strong Buy." The 12-month stock price forecast is $37.5, which is an increase of 98.83% from the latest price.

Price Target

$37.5

(98.83% upside)

Analyst Consensus: Strong Buy